TCGA-44-2661-01A-01R-1107-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- INTERFERON_ALPHA_RESPONSE+0.460
- INTERFERON_GAMMA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.430
- INFLAMMATORY_RESPONSE+0.390
- COMPLEMENT+0.340
- COAGULATION+0.320
- KRAS_SIGNALING_UP+0.320
- BILE_ACID_METABOLISM+0.270
- IL2_STAT5_SIGNALING+0.210
Top 10 suppressed
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V2-0.620
- E2F_TARGETS-0.600
- MITOTIC_SPINDLE-0.570
- WNT_BETA_CATENIN_SIGNALING-0.480
- MYC_TARGETS_V1-0.440
- MTORC1_SIGNALING-0.420
- GLYCOLYSIS-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.380
- HEDGEHOG_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0377 | Med | Medulloblastoma | 0.914 |
| 2 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.904 |
| 3 | TCGA-OR-A5L5-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.876 |
| 4 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.875 |
| 5 | TCGA-BA-A6DB-01A-11R-A30B-07 | — | — | 0.872 |
| 6 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.871 |
| 7 | TCGA-34-5234-01A-01R-1635-07 | — | cohortSQ1 | 0.870 |
| 8 | TCGA-95-8039-01A-11R-2241-07 | — | cohortA1 | 0.868 |
| 9 | SRR8518255 | — | D | 0.866 |
| 10 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |